GSE37283

Gene Expression Changes in Non-Dysplastic Mucosa from Patients with Ulcerative Colitis Harboring Remote Neoplastic Lesions

Whole-study status Not suitable

Dataset does not meet the current suitability threshold.

Whole-study downloads — these do not apply your sample requirements.

Selected cohort requirements

Samples meeting selected requirements: 0 cases / 0 controls

View matching samples

15 case / 5 control samples elsewhere in the study have incomplete or conflicting evidence; they are not included above

Patient pairs verified in indexed sample metadata: 0

A case/control comparison meeting these requirements is not confirmed.

Counts describe samples, not independent patients. Pair verification uses explicit subject identifiers in indexed sample metadata. Zero verified pairs does not establish that the study is unpaired; reported matched-normal design alone is insufficient.

Summary

Background and Aims: Individuals with ulcerative colitis (UC) are at increased risk for colorectal cancer, although underlying mechanisms are incompletely understood. We sought to identify a potential gene expression signature in non-dysplastic distal mucosa that as a “genetic field effect” could be a marker for remote neoplastic lesions. Results: 468 genes were significantly up-regulated and 541 genes were significantly down-regulated >2-fold in UC patients with neoplasia compared to UC patients without neoplasia. Nine genes (ACSL1, BIRC3, CLC, CREM, ELTD1, FGG, S100A9, THBD, and TPD52L1) were progressively and significantly up-regulated from controls to quiescent non-dysplastic UC to UC with neoplasia. Immunostaining of proteins revealed increases in tissue expression of S100A9 and REG1 in UC-associated cancer and in non-dysplastic tissue from UC patients harboring remote neoplasia, compared to UC patients without dysplasia and normal controls. Conclusions: Gene expression changes occur as a field effect in UC patients without active inflammation who harbor a remote dysplastic lesion. Further characterization of these genes and proteins might elucidate pathways of carcinogenesis in IBD and lead to the development of more accurate, less invasive markers of dysplasia in those at increased risk.

Overall design

Microarray assay were conducted on 20 RNA samples isolated from colon mucosa of 20 patients. Of these patients, 5 were normal controls, 4 had quiescent UC, and 11 had UC with neoplasia. Patients were included if they had a previous clinical diagnosis of UC confirmed by an expert GI pathologist, a disease duration > 7 years, and an extent of disease >20 cm proximal to the anal verge.

Source Evidence

4 sources
Source Contribution Status
GEO

Original dataset metadata, sample metadata, source links, and GEO data availability flags.

Sample records
20 GSM samples
Primary source
recount3

Planned trusted source for processed count availability.

No match found
Expression Atlas

Planned source for curated expression experiment links.

No match found
PubMed

Primary GEO citations and related PubMed articles that mention this dataset.

4 linked publications 4 DOIs

Primary publication

  1. Gene signature distinguishes patients with chronic ulcerative colitis harboring remote neoplastic lesions. Inflammatory bowel diseases, 2013
  2. Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis. The Journal of clinical investigation, 2013

Related publications

  1. Screening of characteristic genes in ulcerative colitis by integrating gene expression profiles. BMC gastroenterology, 2021
  2. Unraveling Crucial Mitochondria-Related Genes in the Transition from Ulcerative Colitis to Colorectal Cancer. Drug design, development and therapy, 2024
Available

Metadata Quality Components

Analysis Readiness

Ready after review
97% DE readiness

Contrast completeness

25/25 pts

Both case and control groups are present in the proposed grouping.

Minimum group size

20/20 pts

Each contrast group has at least 2 samples.

Processed data availability

20/20 pts

Processed data is marked available in the GEO index.

Sample decision clarity

15/15 pts

All samples are assigned to a case or control group.

Blocking warnings

7/10 pts

Warnings are present, but none are critical blockers.

Metadata normalization

10/10 pts

Metadata quality is high enough to support downstream handoff.

Blockers

No readiness blockers detected.

Next Steps

  • Verify the proposed sample assignments and case-versus-control comparison against the GEO metadata before using them in DESeq2 or another differential-expression tool.
  • Confirm processed count files and sample identifiers match the exported metadata.

Analysis Preparation Checklist

5/6 ready

Group labels reviewed

Needs review

Siftome proposed case and control labels, but no reviewer confirmation is stored yet.

Open the sample grouping CSV and confirm group labels before analysis.

Minimum sample count met

Ready

Both groups meet the minimum of 2 samples.

Confirm whether the cohort is large enough for the intended statistical analysis.

Processed counts available

Ready

Processed data availability is marked true in the GEO index.

Verify that downloaded processed files contain usable count or expression identifiers.

Ambiguous samples handled

Ready

No review-needed or unassigned samples are present in the proposed grouping.

Review the grouping table for biologically meaningful differences that the automated checks may not detect.

Exclusion decisions recorded

Ready

No hard-excluded samples were detected by the current rules.

Record any manual exclusions in the downstream analysis notes.

Source traceability preserved

Ready

The dataset and sample accessions can be traced back to GEO.

Keep GEO accessions with exported metadata.

Bioinformatician Review

Bioinformatician review required

Ask a bioinformatician to review grouping, count availability, exclusions, and design before DE.

Assay context may require expert handling before DESeq2-style analysis.

Why This Is Ranked Here

Tumor vs normal
Not suitable Dataset does not meet the current suitability threshold.

Applied Review Decisions

No active review decisions affect this ranking.

Derived Classifications

  • Assay differs from search intent Microarray Search intent expects bulk RNA-seq. Assay came from Normalization rules.
  • Disease context Colorectal cancer, inflammatory bowel disease, ulcerative colitis Disease context came from Normalization rules.
  • Likely case group Ulcerative colitis 15 samples
  • Likely control group Healthy control 5 samples

Intent Interpretation

  • Downgrade or exclusion reason Downgraded assay: microarray cohorts are separated from the RNA-seq intent. Derived from current-intent ranking reasons.

Ranking Facts

Supporting evidence

  • Comparison: Disease/model vs control. Specimen: Tissue. Comparison suitability: 0%.
  • Interpreted disease metadata: Colorectal cancer, Inflammatory bowel disease, Ulcerative colitis.
  • Processed data is available for downstream review.
  • External evidence: PubMed links 4 publications; 4 DOIs available: PMID 23388545, PMID 23945234, PMID 34717557, PMID 39071816.
  • Publication context: Gene signature distinguishes patients with chronic ulcerative colitis harboring remote neoplastic lesions.. Inflammatory bowel diseases, 2013. PMID 23388545. DOI 10.1097/MIB.0b013e3182802bac.
  • Publication context: Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis.. The Journal of clinical investigation, 2013. PMID 23945234. DOI 10.1172/JCI65842.
  • Publication context: Screening of characteristic genes in ulcerative colitis by integrating gene expression profiles.. BMC gastroenterology, 2021. PMID 34717557. DOI 10.1186/s12876-021-01940-0.
  • Publication context: 1 additional linked PubMed publications are available.

Cautions

  • Downgraded assay: microarray cohorts are separated from the RNA-seq intent.
  • Disease/control design without a tumor/normal comparison is outside tumor/normal triage.
  • Microarray expression context downgraded below primary bulk RNA-seq for the default tissue ranking.
  • Overall score capped because comparison suitability is weak for the selected search intent.
  • Overall score capped because microarray cohorts should be compared separately from RNA-seq cohorts.
  • Comparison suitability score is below the Phase 1 recommended threshold.

Dataset Warnings

Normalized Fields

71 fields

Sample Group Preview

20 rows shown
Show Hide
Study totals: Case 15 | Control 5 | Unassigned 0 | Excluded 0 | Ambiguous 0 20 rows shown
Group Role Accession Title Source / characteristics Reason
Ulcerative colitis Case GSM915451 Quiescent ulcerative colitis_UCN1 Quiescent ulcerative colitis Tissue: Colon biopsie Case marker detected.
Ulcerative colitis Case GSM915452 Quiescent ulcerative colitis_UCN2 Quiescent ulcerative colitis Tissue: Colon biopsie Case marker detected.
Ulcerative colitis Case GSM915453 Quiescent ulcerative colitis_UCN3 Quiescent ulcerative colitis Tissue: Colon biopsie Case marker detected.
Ulcerative colitis Case GSM915454 Quiescent ulcerative colitis_UCN4 Quiescent ulcerative colitis Tissue: Colon biopsie Case marker detected.
Ulcerative colitis Case GSM915460 Ulcerative colitis with neoplasia_UCD1 Ulcerative colitis with neoplasia Tissue: Colon biopsie Case marker detected.
Ulcerative colitis Case GSM915461 Ulcerative colitis with neoplasia_UCD3 Ulcerative colitis with neoplasia Tissue: Colon biopsie Case marker detected.
Ulcerative colitis Case GSM915462 Ulcerative colitis with neoplasia_UCD4 Ulcerative colitis with neoplasia Tissue: Colon biopsie Case marker detected.
Ulcerative colitis Case GSM915463 Ulcerative colitis with neoplasia_UCD6 Ulcerative colitis with neoplasia Tissue: Colon biopsie Case marker detected.
Ulcerative colitis Case GSM915464 Ulcerative colitis with neoplasia_UCD7 Ulcerative colitis with neoplasia Tissue: Colon biopsie Case marker detected.
Ulcerative colitis Case GSM915465 Ulcerative colitis with neoplasia_UCD8 Ulcerative colitis with neoplasia Tissue: Colon biopsie Case marker detected.
Ulcerative colitis Case GSM915466 Ulcerative colitis with neoplasia_UCD9 Ulcerative colitis with neoplasia Tissue: Colon biopsie Case marker detected.
Ulcerative colitis Case GSM915467 Ulcerative colitis with neoplasia_UCD10 Ulcerative colitis with neoplasia Tissue: Colon biopsie Case marker detected.
Ulcerative colitis Case GSM915468 Ulcerative colitis with neoplasia_UCD11 Ulcerative colitis with neoplasia Tissue: Colon biopsie Case marker detected.
Ulcerative colitis Case GSM915469 Ulcerative colitis with neoplasia_UCD12 Ulcerative colitis with neoplasia Tissue: Colon biopsie Case marker detected.
Ulcerative colitis Case GSM915470 Ulcerative colitis with neoplasia_UCD13 Ulcerative colitis with neoplasia Tissue: Colon biopsie Case marker detected.
Healthy control Control GSM915455 Normal control_CTL1 Normal control Tissue: Colon biopsie Sample-local control marker detected.
Healthy control Control GSM915456 Normal control_CTL2 Normal control Tissue: Colon biopsie Sample-local control marker detected.
Healthy control Control GSM915457 Normal control_CTL3 Normal control Tissue: Colon biopsie Sample-local control marker detected.
Healthy control Control GSM915458 Normal control_CTL4 Normal control Tissue: Colon biopsie Sample-local control marker detected.
Healthy control Control GSM915459 Normal control_CTL5 Normal control Tissue: Colon biopsie Sample-local control marker detected.

Use as Discovery Cohort

External Validation Finder

Carry Siftome's disease, organism, specimen, assay, data type, and accession into a validation project. Uncertain fields remain Unknown.